The Anlon Healthcare IPO GMP is one of the most awaited updates for investors keeping an eye on the pharmaceutical sector. With strong fundamentals and impressive financial growth, Anlon Healthcare Limited is entering the capital market with a ₹121.03 crore book build issue, opening doors for retail and institutional investors.
In this blog, let’s break down Anlon Healthcare IPO GMP trends, price band, lot size, company details, financial performance, and expected listing gains.
Anlon Healthcare IPO GMP Today
The latest Anlon Healthcare IPO GMP (Grey Market Premium) stands at ₹0 (as of August 25, 2025, 09:29 AM). With a price band of ₹86–91 per share, the estimated listing price is expected to be ₹91 per share (at the cap price + today’s GMP).
This indicates no premium in the grey market yet, and the expected percentage gain/loss per share is 0.00%. Based on the last 5 sessions of grey market activities, the GMP trend shows stability without major movement, which might continue till the listing date.
Anlon Healthcare IPO Details
-
IPO Type: Book Build Issue
-
IPO Size: ₹121.03 Crores
-
Fresh Issue: 1.33 Crore Shares
-
Price Band: ₹86 – ₹91 per share
-
Lot Size: 164 shares
-
Retail Minimum Investment: ₹14,104 (164 shares)
-
sNII Investment: 14 lots (2,296 shares) = ₹2,08,936
-
bNII Investment: 68 lots (11,152 shares) = ₹10,14,832
-
IPO Open Date: August 26, 2025
-
IPO Close Date: August 29, 2025
-
Allotment Date: September 1, 2025
-
Listing Date (Tentative): September 3, 2025
-
Listing Exchange: BSE, NSE
About Anlon Healthcare Limited
Founded in 2013, Anlon Healthcare Ltd. is a leading chemical manufacturing company specializing in pharma intermediates and active pharmaceutical ingredients (APIs). The company’s products cater to medicines, nutraceuticals, personal care, and veterinary products.
Key highlights:
-
Manufactures high-purity pharma intermediates & APIs under international pharmacopeia standards (IP, BP, EP, JP, USP).
-
Provides custom chemical manufacturing for clients with high-purity demands.
-
Holds Drug Master File (DMF) approvals from global regulators like ANVISA, NMPA, and PMDA.
-
Has filed 21 DMFs and working on Ketoprofen and Dexketoprofen Trometamol approvals.
-
Strong R&D capabilities with 65 commercial products, 28 at pilot stage, and 49 under testing.
Competitive Strengths of Anlon Healthcare
-
Strong and diversified product portfolio.
-
Experienced promoters & management team.
-
High entry and exit barriers ensure a stable business.
-
In-house testing, quality control, and assurance systems.
-
Focus on quality, environment, health, and safety.
Financial Performance
Anlon Healthcare has shown remarkable growth over the last few years.
Between FY24 and FY25, revenue increased by 81% and PAT grew by 112%, showing robust financial strength.
The market capitalization of Anlon Healthcare IPO is projected at ₹483.68 Cr.
Should You Apply in Anlon Healthcare IPO?
The Anlon Healthcare IPO GMP currently indicates no premium, but investors should not rely only on GMP to make a decision. Instead, consider:
-
Strong revenue and profit growth.
-
Robust global approvals & expanding DMFs.
-
Growing demand for APIs and pharma intermediates in India & globally.
-
Stability of grey market trend.
If you are a long-term investor focusing on the pharma sector’s growth, Anlon Healthcare IPO could be worth considering. However, short-term investors looking for quick listing gains might not see high movement as per the current GMP trend.
Conclusion
The Anlon Healthcare IPO GMP is stable at ₹0, reflecting no immediate grey market buzz. Still, the company’s strong fundamentals, product portfolio, and financial growth make it a significant player in the pharma space.
If you are looking for long-term value in the healthcare and pharmaceutical sector, this IPO deserves attention. Stay tuned for daily updates on Anlon Healthcare IPO GMP, price trends, and expected listing performance.
Comments
0 comment